Partial breast brachytherapy is associated with inferior effectiveness and increased toxicity compared with whole breast irradiation in older patients (Abstract S2-1; Smith GL et al.)
PAM50 HER2-enriched subtype enriches for tumor response to neoadjuvant anthracyclines/Taxane and Trastuzumab/Taxane containing regimens in HER2-positive breast cancer (Abstract S5-2, Cheang M et al.)
NSABP protocol B-34: a clinical trial comparing adjuvant Clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or Tamoxifen or no therapy – final analysis (Abstract S2-3; Paterson AHG et al.)
Neoadjuvant Pertuzumab and Trastuzumab concurrent or sequential with an Anthracycline-containing or concurrent with an Anthracycline-free standard regimen: a randomized phase II Study (TRYPHAENA) (Abstract S5-6; Schneeweiss A et al.)
Neoadjuvant chemotherapy of Paclitaxel with or without Rad001: results of the non-responder part of the GEPARQUINTO study (GBG 44) (Abstract S3-6; Huober J et al.)
